金刚烷胺、莫达非尼与哌甲酯治疗多发性硬化疲劳的随机对照交叉试验
该随机、安慰剂对照、四序列四周期交叉双盲试验在美国两个多发性硬化中心纳入141例伴疲劳且MFIS>33的患者,比较金刚烷胺、莫达非尼、哌甲酯与安慰剂。
要点
- 三种药物改善MFIS均未优于安慰剂,不支持 indiscriminate 用于多发性硬化疲劳。
- 金刚烷胺、莫达非尼、哌甲酯的不良事件报告比例均高于安慰剂。
- 研究期间发生3例严重不良事件,包括肺栓塞、心肌炎和多发性硬化加重住院。
核心结论
- 金刚烷胺、莫达非尼和哌甲酯在改善多发性硬化疲劳方面不优于安慰剂,且不良事件更常见。
- 研究结果不支持不加选择地使用金刚烷胺、莫达非尼或哌甲酯治疗多发性硬化疲劳。
研究设计与样本
- 随机、安慰剂对照、四序列、四周期交叉、双盲试验,在美国两个学术多发性硬化中心招募患者。
- 169例筛查,141例入组并随机分配到四种用药序列之一,136例纳入主要终点意向性分析。
- 受试者报告疲劳且改良疲劳影响量表(MFIS)评分>33,各药最长使用6周,洗脱期2周。
- 主要终点为各用药期第5周最高耐受剂量时的MFIS,采用线性混合效应回归模型分析。
主要发现
- 不良事件报告比例:安慰剂38/124(31%),金刚烷胺49/127(39%),莫达非尼50/125(40%),哌甲酯51/129(40%)。
- 研究期间发生3例严重不良事件:金刚烷胺期间肺栓塞和心肌炎,莫达非尼期间多发性硬化加重需住院。
关键数值与推荐
- 入组要求MFIS评分>33。
- 金刚烷胺口服最高100 mg每日两次,莫达非尼最高100 mg每日两次,哌甲酯最高10 mg每日两次。
- 各用药期最长6周,药物间洗脱期2周。
- 主要终点为第5周最高耐受剂量时的MFIS。
临床怎么用
- 对多发性硬化疲劳患者,不应常规无条件处方金刚烷胺、莫达非尼或哌甲酯。
- 需结合个体情况权衡用药,注意不良事件及严重不良事件风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Methylphenidate, modafinil, and amantadine are commonly prescribed medications for alleviating fatigue in multiple sclerosis; however, the evidence supporting their efficacy is sparse and conflicting. Our goal was to compare the efficacy of these three medications with each other and placebo in patients with multiple sclerosis fatigue. METHODS: In this randomised, placebo-controlled, four-sequence, four-period, crossover, double-blind trial, patients with multiple sclerosis who reported fatigue and had a Modified Fatigue Impact Scale (MFIS) score of more than 33 were recruited at two academic multiple sclerosis centres in the USA. Participants received oral amantadine (up to 100 mg twice daily), modafinil (up to 100 mg twice daily), methylphenidate (up to 10 mg twice daily), or placebo, each given for up to 6 weeks. All patients were intended to receive all four study medications, in turn, in one of four different sequences with 2-week washout periods between medications. A biostatistician prepared a concealed allocation schedule, stratified by site, randomly assigning a sequence of medications in approximately a 1:1:1:1 ratio, in blocks of eight, to a consecutive series of numbers. The statistician and pharmacists had no role in assessing the participants or collecting data, and the participants, caregivers, and assessors were masked to allocation. The primary outcome measure was the MFIS measured while taking the highest tolerated dose at week 5 of each medication period, analysed by use of a linear mixed-effect regression model. This trial is registered with ClinicalTrials.gov, NCT03185065 and is closed. FINDINGS: Between Oct 4, 2017, and Feb 27, 2019, of 169 patients screened, 141 patients were enrolled and randomly assigned to one of four medication administration sequences: 35 (25%) patients to the amantadine, placebo, modafinil, and methylphenidate sequence; 34 (24%) patients to the placebo, methylphenidate, amantadine, and modafinil sequence; 35 (25%) patients to the modafinil, amantadine, methylphenidate, and placebo sequence; and 37 (26%) patients to the methylphenidate, modafinil, placebo, and amantadine sequence. Data from 136 participants were available for the intention-to-treat analysis of the primary outcome. The estimated mean values of MFIS total scores at baseline and the maximal tolerated dose were as follows: 51·3 (95% CI 49·0-53·6) at baseline, 40·6 (38·2-43·1) with placebo, 41·3 (38·8-43·7) with amantadine, 39·0 (36·6-41·4) with modafinil, and 38·6 (36·2-41·0) with methylphenidate (p=0·20 for the overall medication effect in the linear mixed-effect regression model). As compared with placebo (38 [31%] of 124 patients), higher proportions of participants reported adverse events while taking amantadine (49 [39%] of 127 patients), modafinil (50 [40%] of 125 patients), and methylphenidate (51 [40%] of 129 patients). Three serious adverse events occurred during the study (pulmonary embolism and myocarditis while taking amantadine, and a multiple sclerosis exacerbation requiring hospital admission while taking modafinil). INTERPRETATION: Amantadine, modafinil, and methylphenidate were not superior to placebo in improving multiple sclerosis fatigue and caused more frequent adverse events. The results of this study do not support an indiscriminate use of amantadine, modafinil, or methylphenidate for the treatment of fatigue in multiple sclerosis. FUNDING: Patient-Centered Outcomes Research Institute.
引用
- Nourbakhsh B, Revirajan N, Morris B, et al. Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial. Lancet Neurol. 2020. PMID: 33242419. doi:10.1016/S1474-4422(20)30354-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。